Regeneron (REGN) expects Q2 acquired IPR&D charge of USD 127mln, will reduce GAAP and non-GAAP diluted EPS by c. USD 1.00; relates to up front and opt-in payments tied to collaboration and licensing agreements
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#REGENERON PHARMACEUTICALS INC#REGN.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#REGN#DXY#US EQUITIES